COVID-19 Impact on Global Urological Cancer Therapeutics Drugs, Market Insights and Forecast to 2026

1 Study Coverage

• 1.1 Urological Cancer Therapeutics Drugs Product Introduction
• 1.2 Market Segments
• 1.3 Key Urological Cancer Therapeutics Drugs Manufacturers Covered: Ranking by Revenue
• 1.4 Market by Type
  • 1.4.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Type
  • 1.4.2 Xofigo (radium Ra 223 dichloride)
  • 1.4.3 Jevtana (cabazitaxel)
  • 1.4.4 Inlyta (axitinib)
  • 1.4.5 Votrient (pazopanib hydrochloride)
  • 1.4.6 Sutent (sunitinib malate)
  • 1.4.7 Zytiga (abiraterone acetate)
  • 1.4.8 Xtandi (enzalutamide)
  • 1.4.9 Opdivo (nivolumab)
  • 1.4.10 Provenge (sipuleucel-T)
• 1.5 Market by Application
  • 1.5.1 Global Urological Cancer Therapeutics Drugs Market Size Growth Rate by Application
  • 1.5.2 Hospital
  • 1.5.3 Medical Research Laboratory
  • 1.5.4 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): Urological Cancer Therapeutics Drugs Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Urological Cancer Therapeutics Drugs Industry
    • 1.6.1.1 Urological Cancer Therapeutics Drugs Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Urological Cancer Therapeutics Drugs Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Urological Cancer Therapeutics Drugs Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Executive Summary

• 2.1 Global Urological Cancer Therapeutics Drugs Market Size Estimates and Forecasts
  • 2.1.1 Global Urological Cancer Therapeutics Drugs Revenue 2015-2026
  • 2.1.2 Global Urological Cancer Therapeutics Drugs Sales 2015-2026
• 2.2 Urological Cancer Therapeutics Drugs Market Size by Region: 2020 Versus 2026
  • 2.2.1 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
  • 2.2.2 Global Urological Cancer Therapeutics Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Urological Cancer Therapeutics Drugs Competitor Landscape by Players

• 3.1 Urological Cancer Therapeutics Drugs Sales by Manufacturers
  • 3.1.1 Urological Cancer Therapeutics Drugs Sales by Manufacturers (2015-2020)
  • 3.1.2 Urological Cancer Therapeutics Drugs Sales Market Share by Manufacturers (2015-2020)
• 3.2 Urological Cancer Therapeutics Drugs Revenue by Manufacturers
  • 3.2.1 Urological Cancer Therapeutics Drugs Revenue by Manufacturers (2015-2020)
  • 3.2.2 Urological Cancer Therapeutics Drugs Revenue Share by Manufacturers (2015-2020)
  • 3.2.3 Global Urological Cancer Therapeutics Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
  • 3.2.4 Global Top 10 and Top 5 Companies by Urological Cancer Therapeutics Drugs Revenue in 2019
  • 3.2.5 Global Urological Cancer Therapeutics Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.3 Urological Cancer Therapeutics Drugs Price by Manufacturers
• 3.4 Urological Cancer Therapeutics Drugs Manufacturing Base Distribution, Product Types
  • 3.4.1 Urological Cancer Therapeutics Drugs Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Urological Cancer Therapeutics Drugs Product Type
  • 3.4.3 Date of International Manufacturers Enter into Urological Cancer Therapeutics Drugs Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Urological Cancer Therapeutics Drugs Market Size by Type (2015-2020)
  • 4.1.1 Global Urological Cancer Therapeutics Drugs Sales by Type (2015-2020)
  • 4.1.2 Global Urological Cancer Therapeutics Drugs Revenue by Type (2015-2020)
  • 4.1.3 Urological Cancer Therapeutics Drugs Average Selling Price (ASP) by Type (2015-2026)
• 4.2 Global Urological Cancer Therapeutics Drugs Market Size Forecast by Type (2021-2026)
  • 4.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Type (2021-2026)
  • 4.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Type (2021-2026)
  • 4.2.3 Urological Cancer Therapeutics Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
• 4.3 Global Urological Cancer Therapeutics Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Application (2015-2026)

• 5.1 Global Urological Cancer Therapeutics Drugs Market Size by Application (2015-2020)
  • 5.1.1 Global Urological Cancer Therapeutics Drugs Sales by Application (2015-2020)
  • 5.1.2 Global Urological Cancer Therapeutics Drugs Revenue by Application (2015-2020)
  • 5.1.3 Urological Cancer Therapeutics Drugs Price by Application (2015-2020)
• 5.2 Urological Cancer Therapeutics Drugs Market Size Forecast by Application (2021-2026)
  • 5.2.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Application (2021-2026)
  • 5.2.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Application (2021-2026)
  • 5.2.3 Global Urological Cancer Therapeutics Drugs Price Forecast by Application (2021-2026)

6 North America

• 6.1 North America Urological Cancer Therapeutics Drugs by Country
  • 6.1.1 North America Urological Cancer Therapeutics Drugs Sales by Country
  • 6.1.2 North America Urological Cancer Therapeutics Drugs Revenue by Country
  • 6.1.3 U.S.
  • 6.1.4 Canada
• 6.2 North America Urological Cancer Therapeutics Drugs Market Facts & Figures by Type
• 6.3 North America Urological Cancer Therapeutics Drugs Market Facts & Figures by Application

7 Europe

• 7.1 Europe Urological Cancer Therapeutics Drugs by Country
  • 7.1.1 Europe Urological Cancer Therapeutics Drugs Sales by Country
  • 7.1.2 Europe Urological Cancer Therapeutics Drugs Revenue by Country
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 U.K.
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures by Type
• 7.3 Europe Urological Cancer Therapeutics Drugs Market Facts & Figures by Application

8 Asia Pacific

• 8.1 Asia Pacific Urological Cancer Therapeutics Drugs by Region
  • 8.1.1 Asia Pacific Urological Cancer Therapeutics Drugs Sales by Region
  • 8.1.2 Asia Pacific Urological Cancer Therapeutics Drugs Revenue by Region
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 South Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Taiwan
  • 8.1.9 Indonesia
  • 8.1.10 Thailand
  • 8.1.11 Malaysia
  • 8.1.12 Philippines
  • 8.1.13 Vietnam
• 8.2 Asia Pacific Urological Cancer Therapeutics Drugs Market Facts & Figures by Type
• 8.3 Asia Pacific Urological Cancer Therapeutics Drugs Market Facts & Figures by Application

9 Latin America

• 9.1 Latin America Urological Cancer Therapeutics Drugs by Country
  • 9.1.1 Latin America Urological Cancer Therapeutics Drugs Sales by Country
  • 9.1.2 Latin America Urological Cancer Therapeutics Drugs Revenue by Country
  • 9.1.3 Mexico
  • 9.1.4 Brazil
  • 9.1.5 Argentina
• 9.2 Central & South America Urological Cancer Therapeutics Drugs Market Facts & Figures by Type
• 9.3 Central & South America Urological Cancer Therapeutics Drugs Market Facts & Figures by Application

10 Middle East and Africa

• 10.1 Middle East and Africa Urological Cancer Therapeutics Drugs by Country
  • 10.1.1 Middle East and Africa Urological Cancer Therapeutics Drugs Sales by Country
  • 10.1.2 Middle East and Africa Urological Cancer Therapeutics Drugs Revenue by Country
  • 10.1.3 Turkey
  • 10.1.4 Saudi Arabia
  • 10.1.5 U.A.E
• 10.2 Middle East and Africa Urological Cancer Therapeutics Drugs Market Facts & Figures by Type
• 10.3 Middle East and Africa Urological Cancer Therapeutics Drugs Market Facts & Figures by Application

11 Company Profiles

• 11.1 Novartis
  • 11.1.1 Novartis Corporation Information
  • 11.1.2 Novartis Description, Business Overview and Total Revenue
  • 11.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
  • 11.1.5 Novartis Recent Development
• 11.2 Pfizer
  • 11.2.1 Pfizer Corporation Information
  • 11.2.2 Pfizer Description, Business Overview and Total Revenue
  • 11.2.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
  • 11.2.4 Pfizer Urological Cancer Therapeutics Drugs Products Offered
  • 11.2.5 Pfizer Recent Development
• 11.3 Johnson & Johnson
  • 11.3.1 Johnson & Johnson Corporation Information
  • 11.3.2 Johnson & Johnson Description, Business Overview and Total Revenue
  • 11.3.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
  • 11.3.4 Johnson & Johnson Urological Cancer Therapeutics Drugs Products Offered
  • 11.3.5 Johnson & Johnson Recent Development
• 11.4 AstraZeneca
  • 11.4.1 AstraZeneca Corporation Information
  • 11.4.2 AstraZeneca Description, Business Overview and Total Revenue
  • 11.4.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
  • 11.4.4 AstraZeneca Urological Cancer Therapeutics Drugs Products Offered
  • 11.4.5 AstraZeneca Recent Development
• 11.5 Astellas
  • 11.5.1 Astellas Corporation Information
  • 11.5.2 Astellas Description, Business Overview and Total Revenue
  • 11.5.3 Astellas Sales, Revenue and Gross Margin (2015-2020)
  • 11.5.4 Astellas Urological Cancer Therapeutics Drugs Products Offered
  • 11.5.5 Astellas Recent Development
• 11.6 Bristol-Myers Squibb
  • 11.6.1 Bristol-Myers Squibb Corporation Information
  • 11.6.2 Bristol-Myers Squibb Description, Business Overview and Total Revenue
  • 11.6.3 Bristol-Myers Squibb Sales, Revenue and Gross Margin (2015-2020)
  • 11.6.4 Bristol-Myers Squibb Urological Cancer Therapeutics Drugs Products Offered
  • 11.6.5 Bristol-Myers Squibb Recent Development
• 11.7 Abbott Laboratories
  • 11.7.1 Abbott Laboratories Corporation Information
  • 11.7.2 Abbott Laboratories Description, Business Overview and Total Revenue
  • 11.7.3 Abbott Laboratories Sales, Revenue and Gross Margin (2015-2020)
  • 11.7.4 Abbott Laboratories Urological Cancer Therapeutics Drugs Products Offered
  • 11.7.5 Abbott Laboratories Recent Development
• 11.8 Celgene Corporation
  • 11.8.1 Celgene Corporation Corporation Information
  • 11.8.2 Celgene Corporation Description, Business Overview and Total Revenue
  • 11.8.3 Celgene Corporation Sales, Revenue and Gross Margin (2015-2020)
  • 11.8.4 Celgene Corporation Urological Cancer Therapeutics Drugs Products Offered
  • 11.8.5 Celgene Corporation Recent Development
• 11.9 Dendreon Corporation
  • 11.9.1 Dendreon Corporation Corporation Information
  • 11.9.2 Dendreon Corporation Description, Business Overview and Total Revenue
  • 11.9.3 Dendreon Corporation Sales, Revenue and Gross Margin (2015-2020)
  • 11.9.4 Dendreon Corporation Urological Cancer Therapeutics Drugs Products Offered
  • 11.9.5 Dendreon Corporation Recent Development
• 11.10 Ferring Pharmaceuticals
  • 11.10.1 Ferring Pharmaceuticals Corporation Information
  • 11.10.2 Ferring Pharmaceuticals Description, Business Overview and Total Revenue
  • 11.10.3 Ferring Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
  • 11.10.4 Ferring Pharmaceuticals Urological Cancer Therapeutics Drugs Products Offered
  • 11.10.5 Ferring Pharmaceuticals Recent Development
• 11.1 Novartis
  • 11.1.1 Novartis Corporation Information
  • 11.1.2 Novartis Description, Business Overview and Total Revenue
  • 11.1.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
  • 11.1.4 Novartis Urological Cancer Therapeutics Drugs Products Offered
  • 11.1.5 Novartis Recent Development
• 11.12 Indevus Pharmaceuticals Inc
  • 11.12.1 Indevus Pharmaceuticals Inc Corporation Information
  • 11.12.2 Indevus Pharmaceuticals Inc Description, Business Overview and Total Revenue
  • 11.12.3 Indevus Pharmaceuticals Inc Sales, Revenue and Gross Margin (2015-2020)
  • 11.12.4 Indevus Pharmaceuticals Inc Products Offered
  • 11.12.5 Indevus Pharmaceuticals Inc Recent Development
• 11.13 Ipsen
  • 11.13.1 Ipsen Corporation Information
  • 11.13.2 Ipsen Description, Business Overview and Total Revenue
  • 11.13.3 Ipsen Sales, Revenue and Gross Margin (2015-2020)
  • 11.13.4 Ipsen Products Offered
  • 11.13.5 Ipsen Recent Development
• 11.14 Roche Healthcare
  • 11.14.1 Roche Healthcare Corporation Information
  • 11.14.2 Roche Healthcare Description, Business Overview and Total Revenue
  • 11.14.3 Roche Healthcare Sales, Revenue and Gross Margin (2015-2020)
  • 11.14.4 Roche Healthcare Products Offered
  • 11.14.5 Roche Healthcare Recent Development
• 11.15 Sanofi S.A.
  • 11.15.1 Sanofi S.A. Corporation Information
  • 11.15.2 Sanofi S.A. Description, Business Overview and Total Revenue
  • 11.15.3 Sanofi S.A. Sales, Revenue and Gross Margin (2015-2020)
  • 11.15.4 Sanofi S.A. Products Offered
  • 11.15.5 Sanofi S.A. Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)

• 12.1 Urological Cancer Therapeutics Drugs Market Estimates and Projections by Region
  • 12.1.1 Global Urological Cancer Therapeutics Drugs Sales Forecast by Regions 2021-2026
  • 12.1.2 Global Urological Cancer Therapeutics Drugs Revenue Forecast by Regions 2021-2026
• 12.2 North America Urological Cancer Therapeutics Drugs Market Size Forecast (2021-2026)
  • 12.2.1 North America: Urological Cancer Therapeutics Drugs Sales Forecast (2021-2026)
  • 12.2.2 North America: Urological Cancer Therapeutics Drugs Revenue Forecast (2021-2026)
  • 12.2.3 North America: Urological Cancer Therapeutics Drugs Market Size Forecast by Country (2021-2026)
• 12.3 Europe Urological Cancer Therapeutics Drugs Market Size Forecast (2021-2026)
  • 12.3.1 Europe: Urological Cancer Therapeutics Drugs Sales Forecast (2021-2026)
  • 12.3.2 Europe: Urological Cancer Therapeutics Drugs Revenue Forecast (2021-2026)
  • 12.3.3 Europe: Urological Cancer Therapeutics Drugs Market Size Forecast by Country (2021-2026)
• 12.4 Asia Pacific Urological Cancer Therapeutics Drugs Market Size Forecast (2021-2026)
  • 12.4.1 Asia Pacific: Urological Cancer Therapeutics Drugs Sales Forecast (2021-2026)
  • 12.4.2 Asia Pacific: Urological Cancer Therapeutics Drugs Revenue Forecast (2021-2026)
  • 12.4.3 Asia Pacific: Urological Cancer Therapeutics Drugs Market Size Forecast by Region (2021-2026)
• 12.5 Latin America Urological Cancer Therapeutics Drugs Market Size Forecast (2021-2026)
  • 12.5.1 Latin America: Urological Cancer Therapeutics Drugs Sales Forecast (2021-2026)
  • 12.5.2 Latin America: Urological Cancer Therapeutics Drugs Revenue Forecast (2021-2026)
  • 12.5.3 Latin America: Urological Cancer Therapeutics Drugs Market Size Forecast by Country (2021-2026)
• 12.6 Middle East and Africa Urological Cancer Therapeutics Drugs Market Size Forecast (2021-2026)
  • 12.6.1 Middle East and Africa: Urological Cancer Therapeutics Drugs Sales Forecast (2021-2026)
  • 12.6.2 Middle East and Africa: Urological Cancer Therapeutics Drugs Revenue Forecast (2021-2026)
  • 12.6.3 Middle East and Africa: Urological Cancer Therapeutics Drugs Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Porter’s Five Forces Analysis
• 13.5 Primary Interviews with Key Urological Cancer Therapeutics Drugs Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Urological Cancer Therapeutics Drugs Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source